Compare Quest Diagnostics Inc (DGX) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Match Group Inc — how do they compare? Quest Diagnostics Inc trades at $231.19 (market cap $25.48B), while Match Group Inc trades at $41.65 (market cap $9.53B). The key difference: Quest Diagnostics Inc is far larger — about 2.7× Match Group Inc's market cap, and Match Group Inc pays the higher dividend (1.93%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Match Group Inc for 115 Days on average.
| DGX | MTCH | |
|---|---|---|
Market Cap | $25.48B | $9.53B |
Volume | 941,866 | 3,228,794 |
Sector | Health | Media |
52-Week High | $247.45 | $44.40 |
52-Week Low | $173.49 | $28.90 |
Typical Hold Time | 56 Days | 115 Days |
Enterprise Value | $31.23B | $12.49B |
Dividend Yield | 1.49% | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
MTCH trades at $40.86, up 0.59% on the day, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with a P/E of 14.71, net income margin of 20.17%, and consistent cash flow generation. Recent earnings beat expectations in Q2 2026, and positive news highlights product innovation and growth in Hinge.
The outlook is positive, supported by margin expansion and strategic initiatives, but risks include high debt levels and competitive pressures. Wall Street sentiment is bullish with a $42.29 price target, offering modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
